Wednesday, July 8, 2026

biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA

MAIA Biotechnology

Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non

honolulu, USA HQ
2013 Founded
5 Employees
Public company Type
MAIA · NYSE Ticker
Company details

Quick answer

Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non-Small-Cell Lung, Resectable Hepatocellular Carcinoma, Alzheimer Blood Biomarkers. NovaPharmaNews links 8 clinical program(s), 4 drug profile(s), and 10 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 2 (2), phase 1 (2).

Company snapshot

Makai Biotechnology is based in based in Honolulu, Hawaii, USA and specializes in the clinical development of therapeutics. Major projects include, the development of a novel therapeutics for the treatment of cardiac hypertrophy, heart failure and associated pathologies.

  • 6 approved product(s) across US/EU regulatory metadata.
  • 8 active pipeline program(s) linked via ClinicalTrials.gov.
  • 10 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for MAIA Biotechnology. Not investment advice.

Catalysts

Upcoming readouts, regulatory dates, and congress activity.

  • approval

    FDA clears U.S. trial of MAIA lung cancer drug for third-line patients

Recent coverage

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for MAIA Biotechnology.

2 active signals

24 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 7 30d
  • Nova articles 1 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

  • Peer + 0 momentum

    Pfizer

    TA overlap score 39.6

Recent activity

Latest pipeline, patent, and corporate events for MAIA Biotechnology.

  1. Clinical update

    THIO-101 — Phase 2

  2. Clinical update

    THIO-104 — Phase 3

  3. Clinical update

    etrasimod — Phase 2

  4. Clinical update

    Blood ponction — Unknown

  5. Clinical update

    12-Valent Pneumococcal Conjugate Vaccine — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is MAIA Biotechnology?

    Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non-Small-Cell Lung, Resectable Hepatocellular Carcinoma, Alzhe

  • Is MAIA Biotechnology publicly traded?

    Yes. MAIA Biotechnology is listed with ticker MAIA on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does MAIA Biotechnology develop or market?

    We link 19 drug profile(s) where MAIA Biotechnology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/maia-biotechnology#company-drugs.

  • What are the latest developments for MAIA Biotechnology?

    In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does MAIA Biotechnology focus on?

    MAIA Biotechnology focuses on Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non-Small-Cell Lung based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
10
Infectious Disease
5
Oncology
3
Neurology
2